Small-Cap Catalysts to Watch: April 21 - April 25

Stay ahead of the curve with this week’s key catalysts and notable events, curated straight from the latest filings and company press releases. We’ve also included updates on companies presenting at the American Association for Cancer Research (AACR) Annual Meeting 2025, happening April 25–30, 2025, at McCormick Place Convention Center in Chicago, IL—don’t miss what’s moving the market!

Companies presenting at the AACR Annual Meeting 2025 (April 25–30, McCormick Place, Chicago, IL):

ADCT – Showcasing preclinical data on exatecan-based antibody-drug conjugates targeting Claudin-6, PSMA, and ACST2 (April 27, 28, 30)

MBRX – Presenting abstract on next-gen anthracycline, Annamycin (April 28)

FHTX – Hosting virtual investor event to discuss pipeline highlights, including FHD-909 and novel degrader programs (April 29 at 8:00 a.m. ET)

ANL – Sharing progress on multi-specific I-O platform including AN8025 and pan-RAS(ON) inhibitors (April 28, 29)

PDSB – NCI to present clinical data on PDS01ADC, an IL-12 fused ADC (April 29)

CLDI – Poster on systemic virotherapy targeting all metastatic sites accepted for presentation

BOLT – Presenting data from Phase 1 trial of BDC-3042 in advanced cancers (April 29, 30)

EVAX – Revealing new biomarker and immune data from EVX-01 Phase 2 trial (April 29)

HURA – Posters highlighting KVA12123 antibody and IFx-Hu2.0 therapy in advanced melanoma (April 28)

SNTI – Presenting SENTI-202 trial updates and Logic Gate preclinical data (April 27, 29, 30)

INAB – Poster on next-gen γδ T cell engager platform (April 30)

PPBT – Posters on CM24 (pancreatic cancer) and NT219 (colorectal, head/neck cancers) (April 27, 28, 30)

CHRS – Interim Phase 1 data for CHS-114 in HNSCC presented (April 28)

ATNM – Presenting preclinical data on ATNM-400, a novel Actinium-225 radiotherapy (April 27)

CNTX – Highlighting dose selection of CT-95 using MABEL approach (April 28)

PBYI – Presenting clinical data on neratinib (April 28)

GNPX – Preclinical data on Reqorsa® Gene Therapy for KRASG12C NSCLC (April 29)

BCTX – Presenting three posters (April 28, 30)

PYXS – Two posters on micvotabart pelidotin (MICVO), an EDB+FN-targeting ADC (April 28)

IPHA – Abstract on IPH4502, an ADC targeting Nectin-4, selected (April 29) CEO to present company update at AACR Oncology Partnering Event (April 24)

TNGX – Five posters showcasing PRMT5 program data, including combination potential with KRAS inhibitors (April 27–29)

ABP – Oral presentation on ABP-102/CT-P72 preclinical data (April 27)

ERAS – Three poster presentations across multiple days (April 27–29)

OLMA – Poster on OP-3136, a KAT6 inhibitor, in late-breaking session (April 28)

IOBT – Two posters on IO102-IO103 and IO170; co-founder to speak at cancer vaccine session (April 26, 28)

ZNTL – Four posters covering azenosertib's potential and cfDNA as surrogate marker (April 27–29)

AGEN – Oral and poster presentations for BOT/BAL immunotherapy and NEOASIS trial (April 28, 29)

NUVB – Presenting new nonclinical data for taletrectinib in ROS1+ NSCLC (April 29)

ELEV – Late-breaking poster on HER3 ADC, EO-1022 (April 27)

AFMD – Poster on AFM24 dose optimization via exposure-response analysis (April 29)

ABCL – Poster on preclinical PSMA x CD3 T-cell engagers (April 29)

MOLN – Presenting three posters across two days (April 27, 28)

Companies participating in the Planet MicroCap Showcase (April 22-24, 2025, Las Vegas):

PLBY, IDN, HOVR, PPSI, GAME, NXGL, BRIA, LODE, SANG, NRXS, ISPR, ZDGE, CREX, SOTK, IPWR, DMN, AMS, ELUT, CXDO, JCTC, DHX, LCFY

Companies participating at the Centri Capital Conference at the Nasdaq Marketsite in New York City, New York on Tuesday, April 22, 2025:

IPM, FCUV, HTCR, PRSO, AREC

Companies presenting at the World Vaccine Congress taking place April 21-24, 2025, in Washington, D.C.:

DYAI > Mark Emalfarb, Chief Executive Officer, will present on April 23rd

VXRT > Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present on April 23rd

EVAX > will give two presentations and man a booth on April 23rd

Companies presenting at the American Urology Association (AUA) Meeting, which will take place from April 26–29, 2025, in Las Vegas, Nevada:

RLMD > Presentation of an abstract Prospective Open Label Study to Evaluate the Safety and Efficacy of intravesical sustained release Gemcitabine Docetaxel combination (NDV-01) in High Risk NMIBC on April 28

TARA > Two presentations and a panel discussion highlighting the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be featured on April 26th and 28th

EDAP > Expects to have its largest presence at this year's American Urology Association (AUA) Meeting

Other companies with key Catalysts this week:

SNTI > Will participate in the Virtual Investor Closing Bell Series on April 23, 2025, at 4:00 PM ET. CEO Timothy Lu and CMO Kanya Rajangam will provide a corporate overview.

NVNO > CEO Robert Berman will join the Virtual Investor Closing Bell Series on April 22, 2025, at 4:00 PM ET to provide a corporate overview and discuss the company’s implantable venous valve technologies, VenoValve® and enVVe®.

SKYQ > Hosting a live investor webinar on April 24, 2025, at 11:00 AM PDT / 2:00 PM EDT. Topics include the asphalt shingle waste crisis, Sky Quarry’s proprietary solution and revenue model, fuel supply challenges in California, and regulatory support for its national modular waste-to-energy expansion.

BFRG > Inviting investors to a webinar on April 23, 2025, at 4:15 PM ET, hosted by RedChip Companies. CEO Vin Singh will discuss Bullfrog AI’s cutting-edge use of AI and machine learning to transform drug development.

VANI > Participating in a virtual fireside chat on April 24, 2025, hosted by Yi Chen, Ph.D., CFA, of H.C. Wainwright & Co. CEO Adam Mendelsohn, Ph.D., and CMO Lisa Porter, M.D., will discuss the LIBERATE-1 trial—Vivani’s first-in-human study of NPM-115, a twice-yearly GLP-1 implant for chronic weight management.

COCP > Sam Lee, President and Co-CEO, will present a company overview at the Life Science Innovation Northwest (LSINW) 2025 Conference on April 23 at 3:00 p.m. PT. The event takes place April 23–24 at the Seattle Convention Center.

IPSC > Management will be hosting a live fireside chat on April 22 at 10:00 a.m. ET to discuss preclinical CAR-iT programs targeting autoimmune diseases and cancer.

PCSA > Dr. David Young to present at World Orphan Drug Congress USA 2025 on April 24 at 2:00 p.m. ET. Topic: FDA’s Project Optimus in rare diseases.

LPTX > Hosting a virtual KOL event on April 23, 2025, at 2:30 p.m. ET. Dr. Zev A. Wainberg, MD, Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program, will discuss the unmet need in advanced microsatellite stable (MSS) colorectal cancer (CRC) with Leap’s Chief Medical Officer, Dr. Cynthia Sirard.

AMPY > The Company intends to open and immediately adjourn its Special Meeting of Stockholders regarding the proposed merger with Juniper Capital’s upstream Rocky Mountain portfolio companies. The meeting will be reconvened on April 23, 2025, at 9:00 a.m. Central Time.

ZTEK > The company will be presenting "HVAC Energy and CO2eq Savings with Silver-Graphene Oxide Coated Filters" at the ASHRAE International Conference on Energy and Indoor Environment for Hot Climates in Doha, Qatar on April 23-24, 2025.

ESPR > The company will host an in-person R&D Day for analysts and investors on April 24, 2025, starting at 9:00 a.m. ET in New York City. The event will include presentations from company leadership and key opinion leaders, offering a deep dive into Esperion's research and development strategy.

ELUT > The company will debut its EluPro™ Antibiotic-Eluting BioEnvelope, designed for cardiac implantable electronic devices (CIEDs) and neurostimulators, at the Heart Rhythm Society's annual meeting (HRS 2025) from April 25-27, 2025.

DATS > MYSEUM’s strategic sponsorship includes expert advisory, introductions to industry leaders, videos with TPM CEO Cathi Nelson, conference/webinar participation, and year-round brand promotion. DatChat also announced its sponsorship and participation at The Photo Managers Conference, taking place April 22-26, 2025, in San Diego.

AMPX > Amprius CTO Dr. Ionel Stefan will present "Lithium-ion Batteries for Perpetual Stratospheric Platforms" at the Stratospheric Operations and Research Symposium (SOaRS) on April 25, 2025, at 11:20 a.m. CT/9:20 a.m. PT at the 3M Innovation Center in St. Paul, MN.

IRIX > Attending the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, scheduled for April 25–28, 2025, in Los Angeles, California.

AREB > American Rebel Light Beer is sponsoring Tony Stewart Racing drivers Tony Stewart and Matt Hagan as they celebrate Stewart's recent win and head to the American Rebel Light NHRA 4-Wide Nationals, taking place from April 25–27, 2025, at zMAX Dragway at Charlotte Motor Speedway.

ANRO > Presenting at Society of Biological Psychiatry (SOBP) Annual Meeting: April 24-26, 2025.

AUTL > The company will host an R&D investor event on Wednesday, April 23, 2025, at 8:30 a.m. EDT / 1:30 p.m. BST. Autolus will present an update on its clinical pipeline, including plans to expand the obe-cel opportunity, initial data from the ongoing CARLYSLE Phase 1 trial in systemic lupus erythematosus (SLE), and development plans for autoimmune diseases, along with an update on the ongoing commercial launch of AUCATZYL®.

XRTX > The company provided a Type B meeting package to the FDA, as requested, with accompanying FDA communications expected by April 26, 2025. The meeting will include a broad review of chemistry, manufacturing, pharmacology, toxicology, and clinical evidence related to the Company's XRx-026 program for treating gout.

BEAT > The company will present VALID-ECG pivotal study results on 12-lead ECG synthesis software at the Heart Rhythm Society (HRS) meeting, either in San Diego, CA, or online, from April 24-27, 2025. The study forms the basis of the FDA 510(k) submission.

ELAB > Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), announced it has scheduled a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for Wednesday, April 23, 2025. The Type B pre-IND meeting will focus on the path forward for filing an IND for EL-22 as a combination treatment with GLP-1 for muscle preservation.

SGMO > Giroctocogene fitelparvovec (SB-525) is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A, co-developed with and licensed to Pfizer Inc. Sangamo Therapeutics is scheduled to regain development and commercialization rights on April 21, 2025, following Pfizer's decision in December 2024 not to proceed with the Biologics License Application (BLA), Marketing Authorization Application (MAA) submissions, or commercialization of the product.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.